Ability of Periostin as a New Biomarker of Idiopathic Pulmonary Fibrosis
The primarily pathogenesis of IPF, an incurable respiratory disease is believed to over-repair to lung injury. The development of new drugs for IPF has increased the necessity of identifying biomarkers for predicting clinical behavior and the selection of the appropriate treatment strategy for individual patient.
We and another group found that periostin, a matricellular protein expressed specifically in areas of ongoing fibrotic lesions, such as fibroblastic foci in lung tissues from human IPF or murine bleomycin-induced lung injury models. Murine bleomycin-induced lung injury was improved by the constant suppression of periostin expression and treatment with neutralizing anti-periostin antibodies at the fibroproliferative phase. Moreover, total periostin can predict both short-term declines of pulmonary function and overall survival in IPF patients. Our group also established a new enzyme-linked immunosorbent assay (ELISA) kit that is more specific for IPF compared with the conventional kit. This new periostin ELISA kit specifically detects monomeric form, whereas the conventional kit detects both monomeric and oligomeric forms. The monomeric periostin levels can be used to predict pulmonary function decline and to distinguish IPF patients from healthy controls.
In conclusion, periostin may play an important role in fibrogenesis and could be a potential biomarker for predicting disease progression and therapeutic effect in IPF patients.
KeywordsMonomeric periostin Matricellular protein Idiopathic pulmonary fibrosis Fibroblast Myofibroblast Biomarker Interleukin-13 Interleukin-4 TGF-β
We thank the colleagues and collaborators as follows: Kiminori Fujimoto, Koichi Ohshima, Tomotaka Kawayama, Yasuhiko Kitasato, Yuki Sakazaki, Morihiro Tajiri (Kurume University), Koichiro Takahashi, Shinichiro Hayashi, Masaru Uchida, Hiroshi Shiraishi, Kazuto Taniguchi, Shoichi Suzuki, Atsushi Kawaguchi (Saga University), Shigeki Kohno, Noriho Sakamoto (Nagasaki University), Junichi Kadota (Oita University), Masayuki Hanaoka, Hiroshi Yamamoto (Shinshu University), Masao Ichiki (Kyushu Medical Center), Hisako Kushima, Hiroshi Ishii (Fukuoka University), Keiichi Akasaka (Nigata Universtity Medical and Dental Hospital), Hironori Sagara (Syowa University), Takeshi Johkoh (Kinki Central Hospital), Seiya Kato (Saiseikai Fukuoka General Hospital), Hisako Matsumoto (Kyoto University), Yukie Yamaguchi, Michiko Aihara (Yokohama City University), Ayami Kamei, Yoshinori Azuma (Shino-Test Corp.), Simon J. Conway (Indiana University).
- 21.Maher TM, van der Aar EM, Van de Steen O et al (2018) Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respir Med 6:627–635CrossRefGoogle Scholar